Related Experiment Video
Updated: Jun 16, 2026
10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Intravitreal dexamethasone for diabetic macular edema: a pilot study
Carmen K M Chan1, Shaheeda Mohamed, Vincent Y W Lee
1Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
Summary
A single intravitreal dexamethasone injection did not significantly improve diabetic macular edema or visual acuity in a small pilot study. Further research is needed to explore potential benefits of dexamethasone for diabetic macular edema.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Background:
- Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients.
- Intravitreal corticosteroids, such as dexamethasone, are used to treat DME.
- The efficacy and safety of intravitreal dexamethasone for DME require further investigation.
Purpose of the Study:
- To evaluate the effectiveness and safety of intravitreal dexamethasone in treating diabetic macular edema.
- To compare the outcomes of two different dosages of intravitreal dexamethasone (0.4 mg and 0.8 mg).
Main Methods:
- Prospective pilot study involving 12 patients with diabetic macular edema.
- Single intravitreal injection of either 0.4 mg or 0.8 mg dexamethasone.
- Assessment of best-corrected visual acuity and central foveal thickness via optical coherence tomography at 3 months.
Main Results:
- Transient improvements in visual acuity and retinal thickness were observed in both dosage groups.
- No statistically significant changes in visual acuity or retinal thickness were noted at 3 months.
- One patient experienced elevated intraocular pressure (>21 mm Hg); otherwise, no significant adverse events were reported.
Conclusions:
- A single intravitreal injection of dexamethasone (0.4 mg or 0.8 mg) did not demonstrate significant efficacy in treating diabetic macular edema within 3 months.
- The study suggests that a single dose may not be sufficient to achieve meaningful therapeutic effects for DME.
- Further studies with larger sample sizes and longer follow-up periods are warranted to fully assess the role of intravitreal dexamethasone in DME management.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...